RETRACTED: Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol

Badawy, Ahmed; Mosbah, Alaa; Tharwat, Ayman I; Eid, Mohammad

doi:10.1016/j.fertnstert.2008.04.065

Cited by 45 publications

(48 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, Atay [11] also found a pregnancy rate of 21.6% after treatment with 2.5 mg Letrozole and 9.1% after treatment with 100 mg Clomiphene citrate, which was statistically significantly different. There are a few studies that showed significantly higher pregnancy rates with Letrozole than with Clomiphene citrate [15,16].…”

Section: Number Of Pregnanciesmentioning

confidence: 99%

Randomized controlled trial of Letrozole versus Clomiphene citrate for induction of ovulation in polycystic ovarian syndrome (PCOS): A Malaysian experience

Hussain¹,

Ismail²,

Zain³

et al. 2013

OJOG

View full text Add to dashboard Cite

Section: Number Of Pregnanciesmentioning

confidence: 99%

Randomized controlled trial of Letrozole versus Clomiphene citrate for induction of ovulation in polycystic ovarian syndrome (PCOS): A Malaysian experience

Hussain¹,

Ismail²,

Zain³

et al. 2013

OJOG

View full text Add to dashboard Cite

“…The effectiveness of Letrozole for COH has been evaluated mainly in non-oncological patients with polycystic ovary (PCO) (12,13), but only a few reports have studied its effectiveness in women with normal ovaries (14-16).…”

Section: Introductionmentioning

confidence: 99%

Is Letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?

Revelli

Porcu

Levi-Setti

et al. 2013

Gynecological Endocrinology

View full text Add to dashboard Cite

SummaryObjective: To assess the advantages and disadvantages of using Letrozole for controlled ovarian stimulation (COH) in young patients with estrogen receptorpositive (ER+) breast cancer, wishing to cryopreserve oocytes. Design: Retrospective cohort analysis.Setting: Sixteen Italian Units for Reproductive Medicine and In Vitro Fertilization.Methods: Data of 50 ER+ breast cancer patients undergoing COH to cryopreserve oocytes before gonadotoxic chemotherapy with a Letrozole plus gonadotropins (Le+Gn) protocol were compared with those of 25 young women with ER-breast cancer, submitted to COH using a protocol with gonadotropins alone (Gn-only). Results:The Le+Gn protocol implied a significantly lower total Gn consumption and allowed to maintain significantly lower circulating E2 levels at all checkpoints throughout stimulation (peak E2 value 446 ± 357 vs.1553 ± 908 pg/ml, respectively; p=0.001). On the other side, the Le+Gn protocol allowed a significantly lower yield of oocytes available for cryostorage (6.6 ± 3.5 vs. 8 ± 5, respectively; p=0.038).. Conclusions:In breast cancer patients, the association of Letrozole to Gn significantly reduces the number of oocytes available for cryostorage in comparison with the use of Gn alone. On the other side, it is associated with significantly lower E2 levels during the whole stimulation cycle, a safety issue that has been traditionally considered advantageous in case of ER+ cancers.

show abstract

“…The endometrial thickness does not seem to be negatively affected even with doses up to 7.5mg and when used as long as 10 days into a menstrual cycle. [22,25] Furthermore, when looking at pinopod expression and endometrial histology, the use of letrozole resulted in a similar profile to that found during the natural menstrual cycle in ovulatory patients. [26] In addition, uterine artery Doppler indices are favorable in women undergoing letrozole treatment.…”

Section: World Journal Of Pharmaceutical Researchmentioning

confidence: 75%

Glimpse on Splendid Aromatase Inhibitor – Letrozole - A Pragmatic Review

Neerjesh¹

2017

WJPR

View full text Add to dashboard Cite

Letrozole is the third-generation aromatase inhibitor (AI) most commonly used in assisted reproduction. It brings ovulation by inhibiting estrogen production; the consequent hypoestrogenic state enhances GnRH release and pituitary follicle-stimulating hormone (FSH) synthesis. Letrozole has fewer side effects, and a shorter halflife than clomiphene citrate, and no demonstrable effect upon the receptivity of the endometrium. It is effective in treating women with chronic anovulation, unexplained infertility and diminished ovarian reserve. Its safety is superior to clomiphene citrate. Utilizing bioequivalent doses, letrozole pregnancy rates are equal or superior to clomiphene citrate. Several studies reveal situations where it is more efficacious than gonadotropin treatment. A conclusion established was letrozole is as effective as other methods of ovulation induction. Further randomizedcontrolled studies are warranted to define more clearly the efficacy and safety of letrozole in human reproduction.

show abstract

RETRACTED: Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol

Cited by 45 publications

References 15 publications

Randomized controlled trial of Letrozole versus Clomiphene citrate for induction of ovulation in polycystic ovarian syndrome (PCOS): A Malaysian experience

Randomized controlled trial of Letrozole versus Clomiphene citrate for induction of ovulation in polycystic ovarian syndrome (PCOS): A Malaysian experience

Is Letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?

Glimpse on Splendid Aromatase Inhibitor – Letrozole - A Pragmatic Review

Contact Info

Product

Resources

About